콘텐츠로 건너뛰기
Merck
  • Generic MS-based method for the bioanalysis of therapeutic monoclonal antibodies in nonclinical studies.

Generic MS-based method for the bioanalysis of therapeutic monoclonal antibodies in nonclinical studies.

Bioanalysis (2020-02-25)
Noritaka Hashii, Yoshiko Tousaka, Koji Arai, Ryoya Goda, Noriko Inoue, Kazuyuki Murata, Takeshi Okuzono, Satomi Sasahara, Takuma Shigeyama, Hidehisa Tachiki, Shinichi Yamane, Yoshiro Saito, Akiko Ishii-Watabe
초록

Aim: A generic bioanalytical method was developed to quantify therapeutic IgG1 monoclonal antibodies (mAbs) in mouse sera by combining an easy sample preparation method with LC/MS using selected reaction monitoring. Materials & methods: Rituximab and trastuzumab were used as model mAbs. A synthetic stable isotope-labeled peptide or a stable isotope-labeled mAb was used as an internal standard. The method feasibility was evaluated by a collaborative study involving six laboratories. Results: The calibration curve ranged from 1.0 to 1000.0 μg/ml (correlation coefficient >0.99). The validation parameters including selectivity, linearity of calibration curve, accuracy and precision met the predefined acceptance criteria. Conclusion: Our method is a useful bioanalytical method for the quantification of therapeutic IgG mAbs in nonclinical animal studies.